Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
What’s Your Call?
Collective community sentiment on Shukra Pharmaceuticals Ltd
Your Vote -
Buy
58.33%
Hold
16.67%
Sell
25.00%
58.33%
12 users have voted
Option Chain
Analyzes market sentiment, predicts Shukra Pharmaceuticals Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Shukra Pharma - Announcement Under Regulation 30 Of SEBI (LODR)- Strategic PAN India Distribution Tie-Up
-
Shukra Pharma - Reg. 34 (1) Annual Report.
-
Shukra Pharma - Submission Of Notice Of 32Nd AGM Of The Companny.
-
Shukra Pharmaceuticals bags Rs 24.06 cr Government-Backed Supply Contract for Afghanistan
-
Shukra Pharma - Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
-
Shukra Pharma Q1 net profit zooms 110.20% at Rs 1.03 cr
-
Shukra Pharma - Un-Audited Financial Results Of The Company For The First Quarter Ended June 30, 2025, Along With The Auditor
-
Shukra Pharma - Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Held On Wednesday, August 13, 2025
-
Shukra Pharma - Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company Is Scheduled To Be Held On Augu
-
Shukra Pharma - Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements
-
Shukra Pharma - Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements
-
Shukra Pharma - Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements
-
Shukra Pharma has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2025
-
Shukra Pharma - Grant Of Distributorship Rights
-
Shukra Pharma - Strategic Expansion Through Opening Of Branch Offices In Mumbai, Gurgaon(NCR), Bangalore And Kolkata
-
Shukra Pharma - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Shukra Pharma - Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
Key fundamentals
Evaluate the intrinsic value of Shukra Pharmaceuticals Ltd stock
| Name | March-25 | March-24 | March-23 | March-22 | March-21 |
|---|---|---|---|---|---|
| Assets | 67.0125 | 60.7935 | 30.3783 | 19.7265 | 25.3697 |
| Liabilities | 67.0125 | 60.7935 | 30.3783 | 19.7265 | 25.3697 |
| Equity | 43.7879 | 10.947 | 3.9142 | 1.5657 | 1.5656 |
| Gross Profit | 12.7296 | 19.4033 | 5.3633 | 2.8857 | 1.4438 |
| Net Profit | 9.5751 | 18.5372 | 4.4065 | 0.7507 | 0.0338 |
| Cash From Operating Activities | 7.9185 | -5.1967 | 3.1695 | 7.7843 | 0.3715 |
| NPM(%) | 29.38 | 24.85 | 7.48 | 3.66 | 0.3 |
| Revenue | 32.5873 | 74.5729 | 58.8337 | 20.486 | 11.196 |
| Expenses | 19.8577 | 55.1696 | 53.4704 | 17.6003 | 9.7521 |
| ROE(%) | 17.63 | 34.14 | 8.11 | 1.38 | 0.06 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to Shukra Pharmaceuticals Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 809.50 | 0.68 | 73.44 | 15.55 | 301.39 | 0.62 |
| Lotus Eye Hospital and Institute Ltd | 118.70 | -4.24 | 393.23 | 56.65 | 3.55 | 0.00 |
| Bharat Immunological and Biologicals Corporation Ltd | 22.11 | 1.89 | 0.00 | 117.62 | -39.50 | 0.00 |
| Astec Lifesciences Ltd | 860.80 | 0.98 | 0.00 | 53.42 | -604.77 | 0.00 |
Company Info
1998 - Mrs. Riddhi M Patel, director of the company retires by rotation as per Provisions of the Act at this Annual General Meeting. 1999 - In accordance with the Companies Act, 1956 and Articles of Association of the Company, Mr. Mihir M Patel retire by rotation and is eligible for re-appointment. - Company has installed modern energy efficient machines. 2023 -Company issued rights shares of Rs. 10 in the ratio of 6:1 at a premium of Rs. 10 per share. 2024 -The Company has issued Bonus Shares in the Ratio of 3:1.
1998 - Mrs. Riddhi M Patel, director of the company retires by rotation as per Provisions of the Act at this Annual General Meeting. 1999 - In accordance with the Companies Act, 1956 and Articles of Association of the Company, Mr. Mihir M Patel retire by rotation and is eligible for re-appointment. - Company has installed modern energy efficient machines. 2023 -Company issued rights shares of Rs. 10 in the ratio of 6:1 at a premium of Rs. 10 per share. 2024 -The Company has issued Bonus Shares in the Ratio of 3:1.
Read More
Parent Organisation
Shukra Pharmaceuticals Ltd.
Founded
04/03/1993
Managing Director
Mr.Dakshesh Rameshchandra Shah
NSE Symbol
FAQ
The current price of Shukra Pharmaceuticals Ltd is
The 52-week high for Shukra Pharmaceuticals Ltd is
The market capitalization of Shukra Pharmaceuticals Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Shukra Pharmaceuticals Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Shukra Pharmaceuticals Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Shukra Pharmaceuticals Ltd shares.
The CEO of Shukra Pharmaceuticals Ltd is Mr.Dakshesh Rameshchandra Shah, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
